Bladder Cancer

Nivolumab improves outcomes as adjuvant treatment in bladder cancer

September 24, 2020

The positive findings could make nivolumab the new standard of care in the adjuvant setting for patients with muscle-invasive urothelial cancer.

Enfortumab Vedotin shows robust survival outcomes in bladder cancer

September 24, 2020

The antibody-drug conjugate enfortumab vedotin significantly improved overall survival versus chemotherapy in a phase 3 trial.

Sacituzumab Govitecan sustains strong activity in heavily pretreated bladder cancer

September 23, 2020

Pivotal phase 3 trial launched to confirm promising results in metastatic urothelial carcinoma.

Genomic profiling of urothelial cancers finds many with actionable alterations

September 17, 2020

Of 2463 patients with urothelial cancer who underwent comprehensive genomic profiling, 39% harbored ≥1 tier 1-2 genomic alterations.

Disposable cystoscope performs as well as reusable scope in detection of bladder cancer

September 14, 2020

“The grasper disposable scope may fill the gap as an alternative to the conventional reusable cystoscope,” researchers concluded.

Study shows viability of telemedicine approach to cystoscopy

September 14, 2020

Tele-cystoscopy was found equivalent to traditional cystoscopy with respect to identification of abnormalities and action decisions.

Bladder cancer: QoL scores similar whether patients have robotic or open cystectomy

August 26, 2020

Differences following surgery were related to the control of cancer and adjustments with urinary diversion.

Treatment alternatives to radical cystectomy for bladder cancer continue to evolve

August 25, 2020

"Therapeutic strategies are needed in the management of NMIBC that recurs after gold-standard intravesical BCG," Gomella writes.

Antibiotics linked to worse survival outcomes with atezolizumab in bladder cancer

August 20, 2020

Investigators warn of the dangers of overprescribing antibiotics in cancer care.

Durvalumab granted FDA priority review for less-frequent dose in bladder cancer

August 18, 2020

The new dose would reduce a patient’s required medical visits by 50%.

Quality performance initiative may improve TURBT outcomes in bladder cancer

August 14, 2020

Increased usage of bladder diagrams was observed following implementation of the program.

Real-world data demonstrate efficacy of genomic urine test for bladder cancer recurrence

August 07, 2020

Including the genomic test in the protocol for patient surveillance reduced the average number of annual cystoscopies by approximately 39%.

Blue light cystoscopy linked to cost-savings in bladder cancer detection

August 04, 2020

The cost-savings are particularly noteworthy given prior evidence of blue light imaging enhancing the efficacy of diagnostic cystoscopy.

Microhematuria guideline emphasizes risk-stratified approach

July 31, 2020

A multidisciplinary panel outlines criteria for stratifying risk for genitourinary malignancy in patients with microhematuria.

Paclitaxel-hyaluronic acid conjugate induces CR in 75% of patients with bladder CIS

July 24, 2020

Intravesical Oncofid P-B, a conjugate of paclitaxel and hyaluronic acid, is active in patients with carcinoma in situ of the bladder that is not responsive to bacillus Calmette-Guérin.

Pembrolizumab plus nab-paclitaxel active as salvage strategy in urothelial carcinoma

July 24, 2020

Given the efficacy and safety demonstrated, there may be a role going forward for the pembrolizumab/nab-paclitaxel combination in earlier disease stages.

Sequential gemcitabine and docetaxel proves efficacious in NMIBC

July 17, 2020

Intravesical instillations prevent recurrence of non–muscle-invasive bladder cancer.

Is low-intensity surveillance feasible for patients with high-risk NMIBC?

July 15, 2020

The study compared regimens for patients with high-risk non–muscle invasive bladder cancer.

Gene-mediated therapy for high-grade NMIBC delivers positive results in trial

July 14, 2020

72.9% of patients with papillary disease achieved high-grade recurrence-free survival at 3 months after initial treatment.

Cabozantinib shows intriguing activity in heavily pretreated urothelial carcinoma

July 08, 2020

Cabozantinib's single-agent activity opens the potential for combination approaches with immunotherapy in patients with heavily pretreated urothelial carcinoma.